{
  "schema_version": 1,
  "nct_id": "NCT07272343",
  "title": "The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes",
  "status": "RECRUITING",
  "conditions": [
    "Type 2 Diabetes Mellitus (T2DM)",
    "Semaglutide",
    "Caloric Restriction"
  ],
  "source": {
    "name": "ClinicalTrials.gov",
    "nct_id": "NCT07272343",
    "url": "https://clinicaltrials.gov/study/NCT07272343",
    "retrieved": "2026-11-16",
    "modified": "Eligibility criteria structured and coded (SNOMED CT, LOINC, RxNorm) by ChartStays from the ClinicalTrials.gov text; the original text is kept unchanged in eligibility.criteria_text. Criteria curated by the project team, not reviewed by clinicians; pre-screening only.",
    "last_update_posted": "2026-04-02"
  },
  "eligibility": {
    "criteria_text": "Inclusion Criteria:\n\n1. Age 18-75 years;\n2. BMI≥25 kg/m²;\n3. Diagnosed as type 2 diabetes mellitus patients according to the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)\";\n4. HbA1c≤8.5%;\n5. Duration of diabetes ≤3 months, and no use of antihyperglycemic drugs;\n6. Willing to participate in this study, and after full informed consent, agrees to strictly follow the treatment plan and promises to attend follow-up visits on time, and signs the informed consent form.\n\nExclusion Criteria:\n\n1. BMI \\< 25 kg/m²;\n2. Age \\< 18 years, or \\> 75 years;\n3. History of type 1 diabetes, acute pancreatitis, or diabetes secondary to pancreatectomy;\n4. History of bariatric surgery or planned bariatric surgery, or currently attempting weight loss within the past 3 months, or use of weight-loss medications within the past 3 months;\n5. Use of GLP-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, or other related drugs within the past 3 months;\n6. Pregnant or breastfeeding women, or those planning to conceive during the study period;\n7. Patients with severe diseases of important organ systems, such as severe cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, renal insufficiency, hematologic diseases, neurological diseases, or malignancies;\n8. Personal or family history of medullary thyroid carcinoma;\n9. Patients with severe mental disorders or communication barriers that prevent accurate understanding of the study content and compliance with the trial procedures.",
    "sex": "ALL",
    "minimum_age": "18 Years",
    "maximum_age": "75 Years",
    "healthy_volunteers": false
  },
  "structured": [
    {
      "id": "inc-0a",
      "type": "inclusion",
      "kind": "age",
      "label": "Age 18 to 75 years",
      "source_text": "ClinicalTrials.gov age limits: 18 Years minimum, 75 Years maximum",
      "min": 18,
      "max": 75,
      "unit": "years"
    },
    {
      "kind": "lab",
      "label": "BMI 25 kg/m2 or higher",
      "loinc": "39156-5",
      "op": "gte",
      "value": 25,
      "unit": "kg/m2",
      "id": "inc-2",
      "type": "inclusion",
      "source_text": "BMI≥25 kg/m²;"
    },
    {
      "kind": "condition",
      "label": "Type 2 diabetes",
      "primary": true,
      "codes": {
        "snomed": [
          "44054006"
        ]
      },
      "id": "inc-3",
      "type": "inclusion",
      "source_text": "Diagnosed as type 2 diabetes mellitus patients according to the \"Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)\";"
    },
    {
      "kind": "lab",
      "label": "HbA1c 8.5% or lower",
      "loinc": "4548-4",
      "op": "lte",
      "value": 8.5,
      "unit": "%",
      "id": "inc-4",
      "type": "inclusion",
      "source_text": "HbA1c≤8.5%;"
    },
    {
      "kind": "lab",
      "label": "BMI below 25 kg/m2",
      "loinc": "39156-5",
      "op": "lt",
      "value": 25,
      "unit": "kg/m2",
      "id": "exc-1",
      "type": "exclusion",
      "source_text": "BMI < 25 kg/m²;"
    }
  ],
  "free_text": [
    {
      "id": "inc-5",
      "type": "inclusion",
      "text": "Duration of diabetes ≤3 months, and no use of antihyperglycemic drugs;"
    },
    {
      "id": "inc-6",
      "type": "inclusion",
      "text": "Willing to participate in this study, and after full informed consent, agrees to strictly follow the treatment plan and promises to attend follow-up visits on time, and signs the informed consent form."
    },
    {
      "id": "exc-3",
      "type": "exclusion",
      "text": "History of type 1 diabetes, acute pancreatitis, or diabetes secondary to pancreatectomy;"
    },
    {
      "id": "exc-4",
      "type": "exclusion",
      "text": "History of bariatric surgery or planned bariatric surgery, or currently attempting weight loss within the past 3 months, or use of weight-loss medications within the past 3 months;"
    },
    {
      "id": "exc-5",
      "type": "exclusion",
      "text": "Use of GLP-1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, dipeptidyl peptidase-4 inhibitors, thiazolidinediones, or other related drugs within the past 3 months;"
    },
    {
      "id": "exc-6",
      "type": "exclusion",
      "text": "Pregnant or breastfeeding women, or those planning to conceive during the study period;"
    },
    {
      "id": "exc-7",
      "type": "exclusion",
      "text": "Patients with severe diseases of important organ systems, such as severe cardiovascular and cerebrovascular diseases, respiratory diseases, gastrointestinal diseases, renal insufficiency, hematologic diseases, neurological diseases, or malignancies;"
    },
    {
      "id": "exc-8",
      "type": "exclusion",
      "text": "Personal or family history of medullary thyroid carcinoma;"
    },
    {
      "id": "exc-9",
      "type": "exclusion",
      "text": "Patients with severe mental disorders or communication barriers that prevent accurate understanding of the study content and compliance with the trial procedures."
    }
  ],
  "requested_fields_for_inquiry": [
    "age",
    "labs:39156-5",
    "conditions",
    "labs:4548-4"
  ],
  "curation": {
    "method": "manual"
  }
}
